|View printer-friendly version|
|Erytech Announces Trading Resumption of Its Ordinary Shares on Euronext Paris|
NOT FOR DISTRIBUTION IN
Trading in the ordinary shares of
This press release does not constitute an offer to sell or a solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About ERYTECH and eryaspase (GRASPA®)
The company’s lead product, eryaspase, also known under the trade name GRASPA®, consists of an enzyme, L-asparaginase, encapsulated inside donor-derived red blood cells. L-asparaginase depletes asparagine, a naturally occurring amino acid essential for the survival and proliferation of cancer cells. L-asparaginase has been a standard component of multi-agent chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), but side effects limit treatment, especially in adults and patients with weak performance status. With its improved safety profile, eryaspase aims to provide L-asparaginase to patients who cannot tolerate current non-encapsulated asparaginases.
Eryaspase in combination with chemotherapy achieved positive efficacy
and safety results in a Phase 2/3 study in children and adults with
relapsed or refractory ALL and in a Phase 2b clinical study in
second-line metastatic pancreatic cancer. ERYTECH also has an ongoing
Phase 1 clinical study of eryaspase in
ERYTECH produces eryaspase at its own GMP-approved and operational
manufacturing site in
In addition to eryaspase, ERYTECH is developing two other product candidates, erymethionase and eryminase, that focus on using encapsulated enzymes to target cancer metabolism and induce tumor starvation. ERYTECH is also exploring the use of its ERYCAPS platform for developing cancer immunotherapies (ERYMMUNE) and enzyme replacement therapies (ERYZYME).
ERYTECH is listed on
This press release contains forward-looking statements, forecasts and
estimates with respect to the global offering, ERYTECH’s clinical
development plans, business and regulatory strategy, and the anticipated
future performance of ERYTECH and of the market in which it operates.
Certain of these statements, forecasts and estimates can be recognized
by the use of words such as, without limitation, “believes”,
“anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”,
“may”, “will” and “continue” and similar expressions. They include all
matters that are not historical facts. Such statements, forecasts and
estimates are based on various assumptions and assessments of known and
unknown risks, uncertainties and other factors, which were deemed
reasonable when made but may or may not prove to be correct. Actual
events are difficult to predict and may depend upon factors that are
beyond ERYTECH's control. There can be no guarantees with respect to
pipeline product candidates that the candidates will receive the
necessary regulatory approvals or that they will prove to be
commercially successful. Therefore, actual results may turn out to be
materially different from the anticipated future results, performance or
achievements expressed or implied by such statements, forecasts and
estimates. Documents filed by ERYTECH with the U.
This announcement does not, and shall not, in any circumstances
constitute a public offering nor an invitation to solicit the interest
of the public in
The distribution of this document may, in certain jurisdictions, be restricted by local legislations. Persons into whose possession this document comes are required to inform themselves about and to observe any such potential local restrictions.
This announcement is not an advertisement and not a prospectus within
the meaning of Directive 2003/71/EC of the European Parliament and of
the Council of
With respect to the member States of the European Economic Area, no action has been undertaken or will be undertaken to make an offer to the public of the securities referred to herein requiring a publication of a prospectus in any relevant member State. As a result, the securities may not and will not be offered in any relevant member State except in accordance with the exemptions set forth in Article 3(2) of the Prospectus Directive or under any other circumstances which do not require the publication by the Company of a prospectus pursuant to Article 3 of the Prospectus Directive and/or to applicable regulations of that relevant member State.
This document does not constitute an offer to the public in
This document is only being distributed to, and is only directed at,
persons in the
This document does not constitute an offer of securities for sale nor
the solicitation of an offer to purchase securities in